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LETTERS TO THE EDITOR
Serum magnesium and PD ! PTH 5 235 2 (135 3 Mg) 1 (23 3 P)
In conclusion, the results of these studies showed aparathyroid hormone levels
significant negative relationship between serum Mg con-
centrations and PTH levels both in HD and PD patients,in dialysis patients
and that this association is independent of the main factors
regulating parathyroid gland function: Ca, P and vitamin D.To the Editor: We read with interest the articles in-
cluded in the Supplement on renal bone disease published Based on these findings, it is possible to speculate that
hypermagnesemia may have a suppresive effect on PTHrecently [Kidney Int Suppl 73, December 1999], especially
the paper by Couttenye et al on low bone turnover [1]. synthesis and/or secretion. In addition, since a consistent
association of adynamic bone disease and relative hypo-In the discussion of adynamic bone disease (ABD), the
authors briefly refer to the association between hypermag- parathyroidism has been revealed, is possible that hyper-
magnesemia may play a role in the pathogenesis of thisnesemia and low parathyroid hormone (PTH) levels re-
ported by us in a preliminary study [2]. However, in that form of low turnover bone disease.
study the possible colinearity between Mg and other fac-
Juan F. Navarro, Carmen Mora, and Javier Garciators could be not ruled out.
Division of NephrologyWe have recently analyzed, in both hemodialysis (HD) Hospital Nuestra Sen˜ora de Candelaria
[3] and peritoneal dialysis (PD) patients [4] not previously Santa Cruz de Tenerife, Spain
treated with vitamin D derivates, whether the relationship
Correspondence to Juan F. Navarro, M.D., Department of Nephrol-between serum Mg and intact PTH levels is independent
ogy, Hospital Nuestra Sen˜ora de Candelaria, 38010 Santa Cruz de Tene-
of other known factors regulating parathyroid gland func- rife, Tenerife, Spain.
tion. Based on previous studies in our geographic area
showing that a PTH concentration lower than 120 pg/mL REFERENCES
is highly predictive of ABD (positive predictive value,
1. Couttenye MM, D’Haese PC, Verschoren WJ, Behets G,
89%), patients with a PTH level below this value were Schrooten I, De Broe ME: Low bone turnover in patients with
renal failure. Kidney Int 56 (Suppl 73):70–76, 1999diagnosed as having relative hypoparathyroidism [5].
2. Navarro JF, Maci´a ML, Gallego E, Mendez ML, Chahin J, Gar-Therefore, the percentage of subjects having relative hy-
cia-Nieto V, Garcia JJ: Serum magnesium concentration and PTH
poparathyroidism was 47% in HD and 58% in PD. These levels. Is long-term hypermagnesemia a risk factor for adynamic
bone disease? Scand J Urol Nephrol 31:275–280, 1997patients had similar serum calcium (Ca) and phosphorus
3. Navarro JF, Mora C, Jimenez A, Torres A, Macia M, Garcia J:(P) than subjects with a PTH higher than 120 pg/mL.
Relationship between serum magnesium and parathyroid hormone
However, patients with hypoparathyroidism had a signifi- levels in hemodialysis patients. Am J Kidney Dis 34:43–48, 1999
cantly higher serum Mg concentration than the rest: HD, 4. Navarro JF, Mora C, Macia M, Garcia J: Serum magnesium con-
centration is an independent predictor of parathyroid hormone level3.01 6 0.33 versus 2.63 6 0.38 mg/dL, P , 0.001; PD,
in peritoneal dialysis patients. Perit Dial Int 19:455–461, 19992.81 6 0.36 versus 2.21 6 0.34 mg/dL, P , 0.001). Linear- 5. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion
regression analysis showed a highly significant inverse cor- MT, Rodriguez AP, Hernandez A, De Bonis E, Darias E, Gonza-
lez-Posadas JM, Losada M, Rufino M, Felsenfeld AJ, Rodri-relation between Mg and PTH in HD (r 5 20.48, P ,
guez M: Bone disease in predialysis, hemodialysis and CAPD pa-0.001) as well as in PD subjects (r 5 20.70, P , 0.01). tients: Evidence of a better response to PTH. Kidney Int 47:1434–1442,
After controlling for the effect of other variables by partial 1995
correlation analysis in both HD and PD, a positive associa-
tion was observed between P and PTH (r 5 0.43, P ,
0.01; and r 5 0.25, P , 0.05, respectively), whereas a
negative relationship was found between Mg and PTH Home hemodialysis:
(r 5 20.58 and r 5 20.57, P , 0.001, respectively). Finally,
a forward stepwise multiple regression analysis demon- Excellent survival at less cost,
strated that only Mg, alkaline phosphatase (AP) and P
concentrations predicted PTH levels in HD patients (mul- but still underutilized
tiple R 5 0.57, P , 0.001), and only Mg and P in PD
To the Editor: We were interested to read the articlesubjects (multiple R 5 0.59, P , 0.001), as defined by the
by Arkouche et al, describing excellent results from theirfollowing functions:
25-year experience with out-center hemodialysis (HD)
HD ! PTH 5 412.2 2 (156.6 3 Mg) 1 (0.25 3 AP) [1]. In their discussion they state that “few data are yet
available on survival in specific out-center HD popula-1 (21 3 P)
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tions,” citing the rarity of home HD in the United States that is accumulated after the time of entry into the study
[3]. Causal mechanisms flow forward in time from theand Japan. It should be pointed out that out-center HD is
still common in Australia and New Zealand, and excellent perspective of the patient. Future information, which has
not been observed at the time of entry into a study, shoulddata are available through the Australia and New Zealand
Transplant (ANZDATA) Registry [2]. Currently, 43% of not be used to predict risk of future events. An added
complexity in examining the blood pressure–allograft sur-HD patients in New Zealand dialyze at home and 3% in
satellite units, while in Australia the figures are 18% and vival relationship is that elevated BP may not only cause,
but may result from decreased allograft function. Ad-41%, respectively [2]. Our dialysis unit, which was estab-
lished in 1969 and serves a population of 480,000, offers justing for renal function at the time the BP reading is
obtained is appropriate to examine the relationship, inde-only home dialysis. We recently published our 30-year
experience [3] reporting a median survival of 7.75 years pendent of renal function, of BP and allograft failure at
or after that point in time. BP measurements taken at thefor home HD patients who were less selected because no
in-center HD program existed. This patient survival was time when the allograft is failing will tend to be higher
because of worsened renal function. Constructing a “base-superior to hospital HD elsewhere in this region. The
quality of life, survival and cost benefits of home HD that line” covariate derived from later BP readings taken when
the allograft is failing will bias the conclusion about thewere recognized in the 1960s still apply today, a fact not
forgotten here. Geographical isolation, with many patients BP-allograft survival relationship. In regression analyses,
the use of events that occur after the time of entry intoliving in isolated rural areas, and an absence of financial
disincentives to prescribing home HD are other reasons a study to predict future events can lead to illogical results
such as their finding that there was an increased risk offor its continued use. Our experience, which is similar to
that of Arkouche et al, suggests that this very successful allograft failure with increasing average time of follow-
up. Allografts that have better survival have longer follow-technique should be utilized more in other parts of the
world. up times.
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Lowering C-peptide levels and
renoprotective therapy
Blood pressure and prediction To the Editor: In a recent editorial by Hebert on reno-
protective therapy, one of the proposed strategies con-of patient outcome
sisted of lowering C-peptide levels, based on animal evi-
dence and human epidemiological data that elevatedTo the Editor: We were initially encouraged by the
recent publication of Cosio et al [1] that supported our insulin levels promote glomerulosclerosis [1]. Exercise,
weight reduction, and diet low in refined sugars were firststudy that demonstrated an increased rate of allograft
failure with increasing levels of blood pressure (BP) [2]. mentioned to lower C-peptide levels “when these patients
develop renal disease” [1]. However, if that proves unsuc-Upon further review, we have concerns about the use of
BP data during follow-up as if they were baseline charac- cessful, a pharmacological approach, which provides some
concerns, was suggested.teristics. In survival analysis, it is improper to use as a
baseline predictor, covariates constructed on information Dimethylbiguanide (metformin) is proposed as an ap-
